Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

Delayed Quote. Delayed  - 05/27 05:30:02 pm
263.4 CHF   +4.03%
05/27 Novartis, Foundation Medicine, Celgene Invest in Healthcare Infor..
05/27 CHUGAI PHARMACE : Bispecific Antibody 'ACE910/Emicizumab' Phase l Da..
05/27 ROCHE : Prognosis good for Swiss biotech
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
05/23/2016 05/24/2016 05/25/2016 05/26/2016 05/27/2016 Date
247.9(c) 251.1(c) 252.6(c) 253.2(c) 263.4(c) Last
1 118 700 1 372 295 1 310 610 1 225 567 3 572 163 Volume
+0.32% +1.29% +0.60% +0.24% +4.03% Change
More quotes
Financials ( CHF)
Sales 2016 50 925 M
EBIT 2016 18 261 M
Net income 2016 11 603 M
Debt 2016 10 591 M
Yield 2016 3,25%
Sales 2017 53 558 M
EBIT 2017 19 698 M
Net income 2017 12 749 M
Debt 2017 4 976 M
Yield 2017 3,45%
P/E ratio 2016 19,16
P/E ratio 2017 17,42
EV / Sales 2016 4,69x
EV / Sales 2017 4,36x
Capitalization 228 322 M
More Financials
Company
Roche Holding AG operates as a research healthcare company.It operates through the diagnostics and pharmaceuticals segments.The pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience.The diagnostic segment... 
Sector
Pharmaceuticals
Calendar
06/03 | 10:00pmPresentation
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
05/27 Novartis, Foundation Medicine, Celgene Invest in Healthcare Informatics Firm ..
05/27 CHUGAI PHARMACEUTICAL : Bispecific Antibody 'ACE910/Emicizumab' Phase l Data in ..
05/27 ROCHE : Diagnostics Operations Assigned Patent
05/27 ROCHE : Prognosis good for Swiss biotech
05/27 Prognosis good for Swiss biotech
05/27 GENENTECH : ’s Gazyva® Showed Superior Progression-Free Survival Compared ..
05/26 REMINDER : Invitation to Roche Analyst Event at ASCO 2016
05/24 CHUGAI PHARMACEUTICAL : Anti-Cancer Agent 'Avastin,' Obtained Approval for Addit..
05/24 ROCHE : Lariam only to be considered as a last resort, says Defence Committee
05/24 ROCHE : Lariam should be 'drug of last resort' for troops
More news
Sector news : Pharmaceuticals - NEC
04:57aDJBIOGEN : AbbVie's Once-Monthly MS Injection Approved in U.S.
03:40a BIOGEN : and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA(TM) (daclizuma..
03:37a BIOGEN : and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Dacliz..
05/27 ASTRAZENECA : Faslodex demonstrates superiority to Arimidex in Phase III study
05/27 MARKETS RIGHT NOW : Stocks close higher on Wall Street
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/27 Roche's Hematology Franchise Almost 100% Protected From Biosimilars
05/27 Roche's Gazyva beats Rituxan in late-stage lymphoma study
05/26 FDA OKs Behring's single-chain AFSTYLA for hemophilia A
05/25 Gain 50% From This Bidding War, Part II
05/25 Roche CMV test for HSCT patients approved in U.S.
Advertisement
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions